BGM Group Ltd.
BGM evidence brief
What we can confirm
- Market Cap:
- $105.4M
What it means
What to watch
Prepared research question
What matters most for BGM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BGM
BGM Group Ltd. is a Cayman Islands holding company with no direct operations, focused on AI applications, intelligent robots, cloud computing, and biopharmaceuticals, and generates revenue primarily through its Chinese subsidiaries in diversified pharmaceutical and allied products, AI solutions, and insurance businesses [sec · filed 2026-07-21].
Key risk: Holding company structure
Market Cap
$105.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
BGM Group Ltd. is a Cayman Islands holding company with no direct operations, focused on AI applications, intelligent robots, cloud computing, and biopharmaceuticals, and generates revenue primarily through its Chinese subsidiaries in diversified pharmaceutical and allied products, AI solutions, and insurance businesses [sec · filed 2026-07-21].
- BGM Group Ltd. is a Cayman Islands holding company with no business operations of its own; its subsidiaries and VIEs operate in China, manufacturing and distributing pharmaceutical and allied products, AI solutions, and insurance services [sec · filed 2026-07-21].
- Net revenue for the year ended September 30, 2025 was $37.92 million, a 34% increase from $25.10 million in the prior year [sec · filed 2026-07-21].
- As of September 30, 2025, the company reported cash and cash equivalents of approximately $9.82 million, total current assets of $51.55 million, and total current liabilities of $17.86 million [sec · filed 2026-07-21].
- The company estimates it will need at least $50 million in financing over the next three years to execute its business plans, including expanding pharmaceutical and chemical facilities and acquiring traditional Chinese medicine enterprises [sec · filed 2026-07-21].
- The R&D department, led by Mr. Chen Xin, had 17 professionals as of September 30, 2025, three with advanced degrees in Medicine and Traditional Medicine [sec · filed 2026-07-21].
What works
- Revenue grew 34% year-over-year to $37.92 million for the year ended September 30, 2025, indicating expanding commercial activity [sec · filed 2026-07-21].
- The company has a diversified business model spanning pharmaceutical and allied products, AI solutions, and insurance, which may provide multiple revenue streams [sec · filed 2026-07-21].
- The R&D department has 17 professionals and is described as the core of technological innovation, with a focus on improving industry competitiveness [sec · filed 2026-07-21].
What to weigh
- BGM Group Ltd. is a Cayman Islands holding company with no direct operations, relying entirely on its subsidiaries and VIEs for business activities, which introduces structural complexity and risk [sec · filed 2026-07-21].
- The company has limited working capital and states it will need substantial additional financing; it estimates at least $50 million is required over the next three years, and failure to obtain financing could materially harm business plans [sec · filed 2026-07-21].
- The company's financial performance is subject to significant volatility; for example, EBITDA as a percentage of revenue was -1.0% in 2024 and -14.8% in 2023, indicating inconsistent profitability [sec · filed 2026-07-21].
- No revenue is currently derived from international markets, making the company entirely dependent on the Chinese market [sec · filed 2026-07-21].
From the filings
Quoted directly from source documents.
Revenue for FY2025 was $37.92 million
“Our net revenue for the year ended September 30, 2025 was $37.92 million”
SEC filings · July 21, 2026
Cash and cash equivalents as of September 30, 2025
“As of September 30, 2025, we had cash and cash equivalents of approximately $9,820,440”
SEC filings · July 21, 2026
Estimated financing need of at least $50 million over three years
“We estimate that carrying out these business projects will require at least $50 million in the next 3 years.”
SEC filings · July 21, 2026
Risks & what to watch (4)›
Key risks
- Holding company structure — BGM is a Cayman Islands holding company with no operations, relying entirely on subsidiaries/VIEs [sec · filed 2026-07-21].
- Substantial financing need — At least $50 million required over three years; failure to obtain financing could materially harm business plans [sec · filed 2026-07-21].
- Inconsistent profitability — EBITDA/revenue was -1.0% in 2024 and -14.8% in 2023, showing volatile earnings [sec · filed 2026-07-21].
- No international revenue — Currently no revenue from international markets; fully dependent on China [sec · filed 2026-07-21].
What to watch
- Ability to secure at least $50 million in financing over the next three years to fund expansion plans [sec · filed 2026-07-21].
- Revenue growth trajectory and whether the 34% increase in FY2025 can be sustained [sec · filed 2026-07-21].
- Progress of R&D projects and commercialization of new product candidates from the 17-person R&D team [sec · filed 2026-07-21].
- Any changes in Chinese government policies or regulations affecting the pharmaceutical, AI, or insurance sectors [sec · filed 2026-07-21].
Sources: SEC filings · Generated October 3, 2026 · How we verify sources →
Run BGM Group Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BGM Group Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 45,306
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BGM short interestFrequently asked questions
What is the AI investment thesis for BGM Group Ltd.?
BGM Group Ltd. is a Cayman Islands holding company with no direct operations, focused on AI applications, intelligent robots, cloud computing, and biopharmaceuticals, and generates revenue primarily through its Chinese subsidiaries in diversified pharmaceutical and allied products, AI solutions, and insurance businesses [sec · filed 2026-07-21].
Who is the CEO of BGM Group Ltd.?
Ms. Huandi Zhao is the chief executive officer of BGM Group Ltd. (BGM).
Where is BGM Group Ltd. headquartered?
BGM Group Ltd. (BGM) is headquartered in Chengdu, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.